Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

661

Full text

577

Free full text

254

Publication Types

Journal Article

673

Review

285

Research Support, Non-U.S. Gov't

208

Randomized Controlled Trial

151

Comparative Study

145

Multicenter Study

145

Observational Study

Meta-Analysis

Systematic Review

Clinical Trial

Clinical Trial, Phase III

Research Support, N.I.H., Extramural

Case Reports

Network Meta-Analysis

Clinical Trial Protocol

Clinical Trial, Phase II

Letter

Clinical Trial, Phase I

Practice Guideline

Equivalence Trial

Research Support, U.S. Gov't, P.H.S.

Consensus Development Conference

Clinical Trial, Phase IV

Scoping Review

Controlled Clinical Trial

Research Support, U.S. Gov't, Non-P.H.S.

Comment

Validation Study

Historical Article

Publication Year

From

Quick links

Individual year

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Factor Xa Inhibitors""[mesh_terms]

681 Results

Searching titles within these results

Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants?

Paul K L Chin

Seminars in thrombosis and hemostasis 2015;41(2):195-207

Full Text

Abstract

Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis.

Amna Kamil, Sandhiya Prem Kumar, Rumaisa Zulfiqar, Eiman Araib, Bibi Samia Khan, Muhammad Saad Khan, Muhammad Mohsin Khan, Umaimah Naeem, Aminath Waafira

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2025;31():10760296251372947

Full Text

Abstract

Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions.

Tomas Kvasnicka, Ivana Malikova, Zuzana Zenahlikova, Karolína Kettnerova, Radka Brzezkova, Tomas Zima, Jan Ulrych, Jan Briza, Ivan Netuka, Jan Kvasnicka

Current drug metabolism 2018;18(7):636-642

Full Text

Abstract

Insights into direct anticoagulants.

Najib Dally, Elias Saad

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2016;26(5):492-8

Full Text

Abstract

Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.

Thomas F Lüscher, Jan Steffel

Journal of cardiovascular medicine (Hagerstown, Md.) 2009;10(8):616-23

Free Full Text

Abstract

Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants.

Job Harenberg, Shanshan Du, Sandra Krämer, Christel Weiss, Roland Krämer, Martin Wehling

Seminars in thrombosis and hemostasis 2015;41(2):228-36

Free Full Text

Abstract

Meta-Analysis Investigating the Role of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi.

Yehia Saleh, Abdullah Al-Abcha, Ola Abdelkarim, Mahmoud Abdelnabi, Abdallah Almaghraby

The American journal of cardiology 2021;150():126-128

Full Text

Direct oral factor Xa inhibitors for the prevention of non-central nervous systemic embolism patients with non-valvular atrial fibrillation - a systematic review and meta-analysis.

Victoria Gandara, Fernando Vazquez, Esteban Gandara

VASA. Zeitschrift fur Gefasskrankheiten 2016;45(4):293-8

Full Text

Abstract

Principles of reversal of anticoagulation in patients with intracerebral hemorrhage related to oral anticoagulants.

Barbara Casolla, Jørn Dalsgaard Nielsen, Jesper Petersson, Hanne Christensen, Thorsten Steiner, Jennifer A Frontera, Josefine Grundtvig

European stroke journal 2025;10(1_suppl):4-13

Free Full Text

Abstract

A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation.

Richard C Becker, James W Wisler

Critical pathways in cardiology 2012;11(2):55-61

Full Text

Abstract

Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.

Marcelo Sanmartín-Fernández, Domingo Marzal-Martín

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018;23(7):711-724

Free Full Text

Abstract

A new era for anticoagulants.

Massimo Franchini, Pier Mannuccio Mannucci

European journal of internal medicine 2010;20(6):562-8

Full Text

Abstract

Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis.

Christos Karathanos, Petroula Nana, Konstantinos Spanos, George Kouvelos, Alexandros Brotis, Miltiadis Matsagas, Athanasios Giannoukas

Journal of vascular surgery. Venous and lymphatic disorders 2022;9(6):1568-1576.e1

Free Full Text

Abstract

Efficacy and toxicity of factor Xa inhibitors.

Maryna Bondarenko, Christophe Curti, Marc Montana, Pascal Rathelot, Patrice Vanelle

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 2013;16(1):74-88

Free Full Text

Abstract

Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.

Matt Shirley, Sohita Dhillon

Drugs 2016;75(17):2025-34

Full Text

Abstract

Results: 1 – 15 / 681

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Factor Xa Inhibitors""[mesh_terms]

Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants?

Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis.

Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions.

Insights into direct anticoagulants.

Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.

Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants.

Meta-Analysis Investigating the Role of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi.

Direct oral factor Xa inhibitors for the prevention of non-central nervous systemic embolism patients with non-valvular atrial fibrillation - a systematic review and meta-analysis.

Principles of reversal of anticoagulation in patients with intracerebral hemorrhage related to oral anticoagulants.

A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation.

Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.

A new era for anticoagulants.

Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis.

Efficacy and toxicity of factor Xa inhibitors.

Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.

Results for
""Factor Xa Inhibitors""[mesh_terms]